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Leishmaniasis is a life-threatening disease with a worldwide 
distribution and a huge impact especially in immunocompromised 
patients. Nowadays, the use of amphotericin B, an antifungal agent, or 
other marketed strategies to overcome this disease exhibit major 
clinical limitations. Thus, other strategies have been pursued to 
achieve better clinical treatments and decrease toxicity. In this work, 
a promising conjugate based on dextrin and amphotericin B was 
developed. An HPLC-MS detection method was also developed in 
order to determine the amphotericin B concentration and the 
encapsulation efficiency. This water-soluble polymer-drug conjugate 
has shown promising effects against axenic cultures of Leishmania 
amazonensis parasite and infected macrophages, without being 
cytotoxic to the latter. 
 
Leishmaniasis has been classified as one of the most neglected 
tropical diseases that affects around 2 million people worldwide 
(with an incidence of about 0.5 million cases annually) causing 
morbidity and mortality [1]. This disease, which is endemic in 
poor countries, is also found in Europe (transmitted as a 
zoonosis). In fact, there are 12 million people currently infected 
globally and 350 million people in 88 countries all over the 
world living at risk of developing one of the many forms of the 
disease [1, 2]. Protozoan parasites of the genus Leishmania are 
responsible for this life-threatening disease. These parasites can 
maintain their life cycle through transmission between two 
forms: the extracellular motile promastigote found in insects 
(sandfly) and the intracellular non-motile amastigote inside the 
macrophages of mammalian hosts [3]. Similarly to other 
intracellular pathogens, such as Mycobacterium tuberculosis, 
this life-threatening parasite can cause a range of diseases, 
especially in immunocompromised patients [1, 3]. More 
specifically, some Leishmania species (e.g. L. major, L. 
mexicana, L. amazonensis and L. braziliensis) promote 
cutaneous, mucocutaneous or diffuse cutaneous leishmaniasis, 
characterized by localized symptoms. Other Leishmania species 
that are more aggressive (e.g. L. donovani, L. chagasi, L. 
infantum), target internal organs causing visceral leishmaniasis. 
This form of the disease is responsible for approximately 70,000 
deaths per year and is associated to different symptoms: fever, 
weight loss, splenomegaly, hepatomegaly and anemia [2, 3].  
Despite the well-established knowledge and the recent advance 
in our understanding of leishmanial biology, some aspects of this 
disease remain enigmatic and because of that the current control 
or treatment strategies are rather inadequate [3, 4]. This is either 
due to limited availability of effective parenteral drug 
formulations or constant appearance of new fungal infections, 
which are resistant to the available drugs on the market. Besides, 
as there are currently no effective vaccines to prevent human 
leishmaniasis, the management/cure of the disease relies on 
chemotherapy, where the drugs are of high toxicity, low efficacy 
and difficult to administer [2, 5]. Amphotericin B (AMB) - a 
highly toxic water-insoluble compound - is a polyene antibiotic 
used as standard drug for fungal infections. Currently it is 
recommended as a second-line treatment for visceral and 
mucocutaneous leishmaniasis. Nevertheless, this therapy is 
limited since AMB is difficult to solubilize, promote side effects 
(nausea, fever and chills) and is toxic, mainly to the kidneys, 
central nervous system and liver. Considering that, strategies 
such as the use of combination therapy, modification of the 
AMB molecule, modification of the physical state of AMB and 
use of drug delivery system (liposomal formulations, lipid 
complexes, lipid emulsions, colloidal dispersions, among 
others) have been the cornerstones to improve the therapeutic 
efficacy and to reduce the toxicity of AMB, even at high doses. 
However, there are some lipid products (e.g. AmBisome) or 
micellar formulations (e.g. sodium deoxycholate AMB - 
Fungizone) that, despite being on the market, exhibit major 
clinical limitations [5, 6]. 
The use of proteins, polypeptides, polysaccharides and synthetic 
polymers to achieve water-soluble polymer-drug conjugates has 
attracted considerable attention in recent years since it may 
enable drug targeting while reducing drug toxicity [5, 7]. 
Different polymeric drug carriers have been widely studied for 
this purpose, including polysaccharides [5, 7, 8], which possess 
high water-solubility, low toxicity, a high degree of 
biodegradability and biocompatibility [9]. 
In this work, we hypothesize that dextrin may be an interesting 
polysaccharide for the development of a drug delivery system as 
it is a biocompatible and nonimmunogenic material, degradable 
in vivo by amylases, making it a potential asset for use in the 
biomaterials field [10]. Considering that, the purpose of this 
work was to achieve and characterize a new water-soluble 
dextrin-amphotericin B (DEX-AMB) conjugate and test its 
efficacy against Leishmania infection.  
The conjugate, which was obtained by mixing dextrin with 
AMB, was characterized in terms of size/morphology by cryo-
SEM. Furthermore, an HPLC-MS detection method was 
optimized and used to determine the AMB concentration and the 
encapsulation efficiency (EE) in the conjugate. Leishmanicidal 
activity of the DEX-AMB was assessed in vitro in axenic 
cultures of Leishmania amazonensis by resazurin and infected 
bone marrow-derived macrophages stained with different 
fluorescent probes using high-content microscopy (IN Cell 
Analyzer 2000). The cytotoxic effects of the conjugate were 
assessed on bone marrow-derived macrophages by resazurin. 
In terms of size/morphology characterization, cryo-SEM 
analysis has shown that this conjugate has the ability to form 
spherical particles in aqueous solution. Those particles are 
within the nanometric size range, with a hydrodynamic diameter 
of around 100 - 200 nm. This analysis also prove that the 
conjugate is soluble in water, since no signs of drug precipitation 
were observed. 
As previously stated, the development of an HPLC-MS 
quantification method was very important in this work, since it 
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has been found that the commonly used methods, such as 
spectrophotometry or HPLC-UV, are not reliable.  In this work, 
a discussion on the limitations of the commonly used methods 
for estimation of AMB will be provided and a new method is 
proposed. 
In vitro assays were performed to evaluate possible cytotoxic 
effects against bone marrow-derived macrophages and to assess 
capacity of the DEX-AMB to reduce the parasite infection. 
Comparatively to the non-encapsulated AMB, the conjugate 
material showed less cytotoxicity at the higher tested doses. In 
the L. amazonensis-infected bone marrow-derived 
macrophages, all the tested doses of our conjugate promoted a 
slightly higher inhibition of the infection comparatively to the 
non-encapsulated drug. 
In conclusion, this work has shown that DEX-AMB is a 
promising drug delivery system for the treatment of 
Leishmaniasis. This is proved by the capacity of our polymer-
drug conjugate to generate similar effects to the ones obtained 
with non-encapsulated AMB against Leishmania-infected 
macrophages and Leishmania axenic cultures, with the 
advantage of being significantly less cytotoxic. 
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